PMID- 29932335
OWN - NLM
STAT- MEDLINE
DCOM- 20181214
LR  - 20200930
IS  - 1530-6992 (Electronic)
IS  - 1530-6984 (Linking)
VI  - 18
IP  - 7
DP  - 2018 Jul 11
TI  - Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled 
      Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
PG  - 4377-4385
LID - 10.1021/acs.nanolett.8b01406 [doi]
AB  - Dendritic cells (DCs) are increasingly used in cancer vaccines due to their 
      ability to regulate T-cell immunity. Major limitations associated with the 
      present DC adoptive transfer immunotherapy are low cell viability and transient 
      duration of transplanted DCs at the vaccination site and the lack of recruitment 
      of host DCs, leading to unsatisfactory T-cell immune response. Here, we developed 
      a novel vaccine nodule comprising a simple physical mixture of the peptide 
      nanofibrous hydrogel, anti-PD-1 antibodies, DCs, and tumor antigens. Upon 
      subcutaneous injection, the vaccine nodule maintained the viability and 
      biological function including the antigen uptake and maturation of encapsulated 
      DCs and simultaneously recruited a number of host DCs and promoted the drainage 
      of activated DCs to lymph nodes, resulting in enhanced proliferation of 
      antigen-specific splenocytes and provoking potent cellular immune responses. 
      Compared with adoptive transfer of DCs and subcutaneous administration of antigen 
      vaccine, such a vaccine nodule shows superior antitumor immunotherapy efficiency 
      in both prophylactic and therapeutic tumor models including delayed tumor growth 
      and prolonged mice survival due to effective stimulation of antitumor T-cell 
      immunity and increased infiltration of activated CD8(+) effector T-cells in the 
      tumor. Our findings provide a simple and robust vaccination strategy for DC-based 
      vaccines and also a unique vaccine product for stimulating and enhancing T-cell 
      immunity, holding great promise for immunotherapy against cancer and infectious 
      diseases.
FAU - Yang, Pengxiang
AU  - Yang P
AD  - Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical 
      Engineering , Chinese Academy of Medical Sciences and Peking Union Medical 
      College , Tianjin 300192 , China.
AD  - Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical 
      Science , Harbin Medical University , Harbin 150081 , China.
FAU - Song, Huijuan
AU  - Song H
AD  - Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical 
      Engineering , Chinese Academy of Medical Sciences and Peking Union Medical 
      College , Tianjin 300192 , China.
FAU - Qin, Yibo
AU  - Qin Y
AD  - Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical 
      Engineering , Chinese Academy of Medical Sciences and Peking Union Medical 
      College , Tianjin 300192 , China.
FAU - Huang, Pingsheng
AU  - Huang P
AD  - Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical 
      Engineering , Chinese Academy of Medical Sciences and Peking Union Medical 
      College , Tianjin 300192 , China.
FAU - Zhang, Chuangnian
AU  - Zhang C
AD  - Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical 
      Engineering , Chinese Academy of Medical Sciences and Peking Union Medical 
      College , Tianjin 300192 , China.
FAU - Kong, Deling
AU  - Kong D
AUID- ORCID: 0000-0002-5520-0769
AD  - Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical 
      Engineering , Chinese Academy of Medical Sciences and Peking Union Medical 
      College , Tianjin 300192 , China.
AD  - State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences , 
      Nankai University , Tianjin 300071 , China.
AD  - Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Cancer 
      Institute, Xuzhou Medical University , Xuzhou 221004 , Jiangsu , China.
FAU - Wang, Weiwei
AU  - Wang W
AUID- ORCID: 0000-0003-0333-0868
AD  - Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical 
      Engineering , Chinese Academy of Medical Sciences and Peking Union Medical 
      College , Tianjin 300192 , China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180628
PL  - United States
TA  - Nano Lett
JT  - Nano letters
JID - 101088070
RN  - 0 (Cancer Vaccines)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Peptides)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 25852-47-5 (Hydrogel, Polyethylene Glycol Dimethacrylate)
SB  - IM
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Cell Engineering
MH  - Dendritic Cells/cytology/*immunology
MH  - Humans
MH  - Hydrogel, Polyethylene Glycol Dimethacrylate/therapeutic use
MH  - Neoplasms/immunology/*therapy
MH  - Peptides/immunology/therapeutic use
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors/immunology
MH  - T-Lymphocytes/*immunology
OTO - NOTNLM
OT  - Dendritic cells
OT  - T-cell immunity
OT  - adoptive cell transfer
OT  - peptide nanofibrous hydrogel
OT  - tumor immunotherapy
EDAT- 2018/06/23 06:00
MHDA- 2018/12/15 06:00
CRDT- 2018/06/23 06:00
PHST- 2018/06/23 06:00 [pubmed]
PHST- 2018/12/15 06:00 [medline]
PHST- 2018/06/23 06:00 [entrez]
AID - 10.1021/acs.nanolett.8b01406 [doi]
PST - ppublish
SO  - Nano Lett. 2018 Jul 11;18(7):4377-4385. doi: 10.1021/acs.nanolett.8b01406. Epub 
      2018 Jun 28.